a Cure or the Drug Discovery Gp
FRanK l. DoUGlaS, P.D., m.D.
Prtr, Pur Tc Vturs; Fudr, mIT Ctr r Bidic Ivti;Sir Fw, ewig mri Ku Fudti
Recently, the Kauman Foundation launched a new ocus on translational medicine—the process o turning scientic breakthroughs in the lab into new drugs and other patient therapies, oten delivered by startup companies.Despite the growing sophistication and promise o health care technologyresearch, ewer and ewer breakthrough ideas are nding their way out o research institutions and into the hands o experienced clinicians and medical product development teams. Patients suer as a result, because promisingresearch and innovation are not being translated into new treatments.Progress is being stifed by a crucial gap in the current research and development pipeline: expertise and unding or early-stage innovations. Manyo the biotech startups, academic institutions, and government research centersthat perorm critical early-stage work do not have the resources to move theirbreakthroughs urther along the commercialization pipeline. At the same time,large pharmaceutical companies and venture capitalists are reluctant to investin early-stage research that lacks proven market potential and requires a longer period o time to produce returns on investment. And ederal investment inmedical research is tight—the 2008 budget or the National Institutes o Health isonly about 1 percent higher than its 2007 budget.
Kauman Thoughtbook 2009
. ©2008 by the Ewig mrio Ku oudtio. all rights reserved.